Biochemical and biophysical research communications, 2020-09, Vol.530 (3), p.520-526
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation
- Ist Teil von
- Biochemical and biophysical research communications, 2020-09, Vol.530 (3), p.520-526
- Ort / Verlag
- United States: Elsevier Inc
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- PIK3CA-related overgrowth spectrum is caused by mosaicism mutations in the PIK3CA gene. These mutations, which are also observed in various types of cancer, lead to a constitutive activation of the PI3K/AKT/mTOR pathway, increasing cell proliferation. Heat shock transcription factor 1 (HSF1) is the major stress-responsive transcription factor. Recent findings indicate that AKT phosphorylates and activates HSF1 independently of heat-shock in breast cancer cells. Here, we aimed to investigate the role of HSF1 in PIK3CA-related overgrowth spectrum. We observed a higher rate of proliferation and increased phosphorylation of AKT and p70S6K in mutant fibroblasts than in control cells. We also found elevated phosphorylation and activation of HSF1, which is directly correlated to AKT activation. Specific AKT inhibitors inhibit HSF1 phosphorylation as well as HSF1-dependent gene transcription. Finally, we demonstrated that targeting HSF1 with specific inhibitors reduced the proliferation of mutant cells. As there is currently no curative treatment for PIK3CA-related overgrowth spectrum, our results identify HSF1 as a new potential therapeutic target. •PIK3CA-related overgrowth spectrum is characterized by increased cell proliferation.•Strong activation of HSF1 is found in PIK3CA-related overgrowth spectrum fibroblasts.•AKT inhibitors reduces HSF1 activation and HSF1-dependent gene transcription.•HSF1 inhibition blocks the PIK3CA-related overgrowth spectrum proliferation.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0006-291XeISSN: 1090-2104DOI: 10.1016/j.bbrc.2020.04.146Titel-ID: cdi_hal_primary_oai_HAL_hal_03491260v1
- Format
- –
- Schlagworte
- Cell Proliferation - drug effects, Cells, Cultured, Class I Phosphatidylinositol 3-Kinases - genetics, Class I Phosphatidylinositol 3-Kinases - metabolism, Drug Discovery, Fibroblasts - drug effects, Fibroblasts - metabolism, Fibroblasts - pathology, Heat Shock Transcription Factors - antagonists & inhibitors, Heat Shock Transcription Factors - metabolism, HSF1, Humans, Life Sciences, Lipoma - drug therapy, Lipoma - genetics, Lipoma - metabolism, Lipoma - pathology, Molecular Targeted Therapy, Musculoskeletal Abnormalities - drug therapy, Musculoskeletal Abnormalities - genetics, Musculoskeletal Abnormalities - metabolism, Musculoskeletal Abnormalities - pathology, Mutation, Nevus - drug therapy, Nevus - genetics, Nevus - metabolism, Nevus - pathology, Phosphorylation - drug effects, PI3K, Proto-Oncogene Proteins c-akt - antagonists & inhibitors, Proto-Oncogene Proteins c-akt - metabolism, Segmental overgrowth spectrum, Signal Transduction - drug effects, Vascular Malformations - drug therapy, Vascular Malformations - genetics, Vascular Malformations - metabolism, Vascular Malformations - pathology